PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\', \'Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.\', \'SymRay Biopharma LLC., Shanghai, China.\', \'Acrobiosystems Inc., Beijing, China.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/biot.202100207
?:doi
?:hasPublicationType
?:journal
  • Biotechnology journal
is ?:pmid of
?:pmid
?:pmid
  • 34379353
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.125
?:rankingScore_hIndex
  • 63
is ?:relation_isRelatedTo_publication of
?:title
  • Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34379353>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34379353>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all